2 results
Approved WMOCompleted
The primary objective is to show that eplerenone treatment reduces progression of disease in presymptomatic PLN R14del-carriers
Approved WMORecruiting
Primary: • Demonstrate superior efficacy (increased progression-free survival [PFS]) of MEK162 vs. physician*s choice of selected chemotherapies (liposomal doxorubicin, paclitaxel and topotecan)Key Secondary: • Demonstrate superior efficacy (…